重组干扰素免疫治疗期间缺陷单核细胞功能的增强
Enhancement of defective monocyte function during immunotherapy with recombinant interferon.
作者信息
Nielsen H, Ernst P
出版信息
Cancer Immunol Immunother. 1986;22(2):144-7. doi: 10.1007/BF00199129.
The influence of immunotherapy with high dose (50 X 10(6) units/m2) recombinant leukocyte A interferon on blood monocyte functions was studied in eight patients with bronchogenic carcinoma. Monocyte chemotactic responsiveness (MCR) was initially depressed (9.8 +/- 1.6 cells/field) compared to healthy controls (17.6 +/- 5.1 cells/field), P less than 0.01. Recombinant interferon was administered three times weekly, and after 7 days a significant improvement in chemotaxis was observed (16.6 +/- 3.0 cells/field), P less than 0.05. The MCR remained normal until cessation of interferon therapy (greater than 1 month). Phagocytic and candidacidal activities were normal in the patients and were not influenced by treatment with interferon. In conclusion, high dose recombinant interferon given to cancer patients caused a normalization of defective blood monocyte chemotaxis, which persisted for greater than 1 month.
对8例支气管肺癌患者研究了高剂量（50×10⁶单位/平方米）重组白细胞A干扰素免疫治疗对血液单核细胞功能的影响。与健康对照者（17.6±5.1个细胞/视野）相比，单核细胞趋化反应性（MCR）最初降低（9.8±1.6个细胞/视野），P<0.01。重组干扰素每周给药3次，7天后观察到趋化性有显著改善（16.6±3.0个细胞/视野），P<0.05。在干扰素治疗停止前（超过1个月），MCR一直保持正常。患者的吞噬和杀念珠菌活性正常，且不受干扰素治疗的影响。总之，给予癌症患者高剂量重组干扰素可使缺陷的血液单核细胞趋化性恢复正常，且这种情况持续超过1个月。
Zotero 插件